Ask Dr. Durie - Doctors' Edition: Proteasome Inhibitors in Multiple Myeloma

The following are excerpts from the IMF and Medscape Education Oncology CME activity Ask Dr. Durie - Doctors' Edition: Proteasome Inhibitors in Multiple Myeloma.
 
To view the activity in its entirety and receive CME/ABIMMOC credit, go to: 
https://www.medscape.org/viewarticle/890372?src=acdmpart_imf_890372
 

Visit Medscape.org to register free of charge. 



Section 1. What Are Proteasome Inhibitors and How Are They Used to Treat Multiple Myeloma?
Join Dr Durie as he introduces how proteasome inhibitors are used in multiple myeloma.
Brian Durie, MD

   


Section 2. How Are Proteasome Inhibitors Used in Frontline Therapy?
Learn how proteasome inhibitors are incorporated into treatment for patients with newly diagnosed multiple myeloma.
Brian Durie, MD; Shaji Kumar, MD

   


Section 3. Does High-Risk Disease Impact Proteasome Inhibitor-Based Therapy Selection?
Learn how proteasome inhibitors are used for patients with high-risk disease.
Brian Durie, MD; Saad Z. Usmani, MD

   


Section 4. How Are Proteasome Inhibitors Used in the Relapsed Setting?
Learn what to consider when selecting therapy for patients with relapsed multiple myeloma.
Brian Durie, MD; Thomas Martin, MD

   


Section 5. What Are the Adverse Events Associated With Proteasome Inhibitors And How Are They Managed?
Learn how to manage proteasome inhibitor-related adverse events.
Brian Durie, MD; Joseph Mikhael, MD

   


Section 6. Program Highlights
Dr Durie summarizes key components for using proteasome inhibitors.
Brian Durie, MD